The Priority Review acceptance and absence of an AdCom are strong positive signals. Monitor for any FDA review updates or potential manufacturing/CMC questions ahead of the November 27 PDUFA. The stock may re-rate upward as approval probability increases. Watch for any competitive developments or regulatory setbacks in Europe.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $66.44entry
- T+1 · 6mo ago +3.03%α +2.47% · $68.45
- T+5 · 6mo ago −3.85%α −5.06% · $63.88
- T+20 · 5mo ago +4.89%α +6.79% · $69.69
- T+60 · 3mo ago +24.83%α +22.95% · $82.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of November 27, 2026. The FDA is not planning an advisory committee meeting, and the company is poised to launch upon approval. This is a major regulatory milestone for a first-in-class therapy addressing a significant unmet need in a rare, progressive muscular dystrophy.
Key Facts
- FDA accepted NDA for BBP-418 with Priority Review; PDUFA target action date November 27, 2026.
- FDA not currently planning an advisory committee meeting to discuss the application.
- BBP-418 met all primary and secondary endpoints in Phase 3 FORTIFY trial at 12-month interim analysis.
- If approved, BBP-418 would be the first and only approved therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD.
- Approximately 7,000 individuals in the U.S. and Europe live with LGMD2I/R9 and other addressable α-dystroglycanopathies.
- BBP-418 has Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from FDA; may qualify for a Priority Review Voucher upon approval.
- Company intends to initiate clinical studies in patients under 12 years old and in LGMD2M/R13 and LGMD2U/R20.
Financial Impact
First-in-class therapy for ~7,000 patients in U.S./Europe; potential for significant revenue if approved, with pricing typical for rare disease drugs (often $100K-$500K+/year). No financial terms disclosed.
Risk Factors
- FDA could issue a Complete Response Letter (CRL) at PDUFA date, particularly on CMC or safety grounds.
- Commercial uptake depends on pricing, reimbursement, and physician adoption for a novel therapy in a small patient population.
- Clinical data from ongoing pediatric and additional indication studies could reveal safety or efficacy issues.
- Competition from other LGMD therapies in development could emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301817 |
Track record
38 reports on BBIO
9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers